Genetobe Inc.

Genetobe Inc. is a Michigan-based biotechnology company focused on developing innovative therapies for rare and complex genetic diseases. Registered in SAM.gov since February 2021, the company operates as a for-profit organization that specializes in advanced medical research, particularly in the areas of gene editing, precision medicine, and targeted therapeutic interventions. Through its federal grant awards, Genetobe demonstrates expertise in developing novel molecular compounds and gene therapy technologies aimed at addressing challenging medical conditions across multiple organ systems and disease states.

The company has secured multiple significant federal grant awards from civilian health research agencies, including the National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institute on Alcohol Abuse and Alcoholism, and National Human Genome Research Institute. Genetobe's grant-funded research has focused on developing sophisticated therapeutic approaches such as CRISPR-based gene editing tools for conditions like cystic fibrosis, Type 1 CRISPR tools for gene therapy, precision medicine strategies for alcohol-associated liver disease, and genome editing therapies for Usher Syndrome Type 3. Their research predominantly involves preclinical studies utilizing advanced technologies like AI-assisted drug design, RNAi genetic interventions, and innovative gene editing techniques. The projects typically involve developing novel molecular compounds, testing therapeutic strategies in specialized animal models, and preparing foundational research for potential future clinical trials, with awards ranging from approximately $293,000 to $613,000.